SCHEMBL6329182

SCHEMBL6329182

N#Cc1cccc(CN2CCC(CNC(=O)c3cc(Cl)c(N)[nH]c3=O)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 3/20 0.47
DRD2 P14416 3/20 0.47
DRD4 P21917 3/20 0.47
DRD3 P35462 2/20 0.47
CCR3 P51677 1/20 0.46
HDAC3 O15379 3/20 0.46
HDAC4 P56524 3/20 0.46
HDAC1 Q13547 3/20 0.46
HDAC7 Q8WUI4 3/20 0.46
HDAC2 Q92769 3/20 0.46
HDAC10 Q969S8 3/20 0.46
HDAC11 Q96DB2 3/20 0.46
HDAC8 Q9BY41 3/20 0.46
HDAC6 Q9UBN7 3/20 0.46
HDAC9 Q9UKV0 3/20 0.46
HDAC5 Q9UQL6 3/20 0.46
ACHE P22303 1/20 0.46
KCNH2 Q12809 1/20 0.45
CACNA1I Q9P0X4 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6335672 0.91 HTR4 (0.52) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6329054 0.89 TP53 (0.57) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6329269 0.88 DRD2 (0.58) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL7254822 0.87 HTR4 (0.49) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6328740 0.87 HDAC3 (0.50) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6328378 0.87 CXCR4 (0.52) HTR4DRD2DRD4DRD3KCNH2
SCHEMBL6336876 0.85 HTR4 (0.54) HTR4DRD2DRD4DRD3CCR3
SCHEMBL6329113 0.85 KCNH2 (0.65) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6336358 0.85 HTR4 (0.56) HTR4DRD2DRD4DRD3ACHE
SCHEMBL6329068 0.85 HTR4 (0.56) HTR4DRD2DRD4DRD3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US disclosed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators HRH4, HRH2, HTR4 HTR4 3/4885DRD2 262/4885DRD4 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.